BPMC

Blueprint Medicines Corporation

105.76 USD
-0.38 (-0.36%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Blueprint Medicines Corporation stock is up 0.28% since 30 days ago. The next earnings date is Jul 31, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 60% of the previous 9 June’s closed higher than May. In the last 10 Unusual Options Trades, there were 10 PUTs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
03 Jun 19:35 19 Dec, 2025 110.00 PUT 27 257
03 Jun 19:38 19 Dec, 2025 105.00 PUT 50 0
03 Jun 19:51 19 Dec, 2025 105.00 PUT 20 0
03 Jun 19:54 19 Dec, 2025 105.00 PUT 20 0
03 Jun 19:56 19 Dec, 2025 105.00 PUT 20 0
03 Jun 19:58 19 Dec, 2025 105.00 PUT 24 0
04 Jun 18:29 19 Dec, 2025 110.00 PUT 17 257
05 Jun 17:42 19 Jul, 2024 100.00 PUT 100 23
06 Jun 18:45 19 Dec, 2025 115.00 PUT 16 0
12 Jun 14:39 18 Oct, 2024 110.00 PUT 60 23

About Blueprint Medicines Corporation

Blueprint Medicines Corporation develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor, is developing Fisogatinib.